Midkine, Recombinant, Human (MK, Neurite Growth Promoting Factor-2, NEGF-2)

Human Midkine (MK) is a new member of the heparin-binding neurotrophic factor family. MK and PTN (Pleiotrophin) are structural homologs, and are highly conserved among species. MK plays important roles in development and carcinogensis and has several important biological effects, including promotion of neurite extension and neuronal survival. Recombinant Midkine is a 13.4kD protein, comprising of 123 amino acid residues.\n\nBiological

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M3896

Size

5ug

Form

Supplied as a sterile filtered, lyophilized powder from PBS, pH 7.4. Reconstitute with sterile dH2O, carrier protein to 0.1-1mg/ml

Purity

(same/more than) 98% by SDS-PAGE and HPLC. Endotoxin: (same/less than) 0.1ng/ug (1EU/ug).

References

1. [Expression of midkine in patients with acute myeloid leukemia and its significance.]\n\nZhongguo Shi Yan Xue Ye Xue Za Zhi 2006 Jun;14(3):442-5\n\n2. Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer.\n\nCancer Sci 2006 Jun 23;\n\n3. [Expression of midkine in eutopic and ectopic endometrium of patients with severe endometriosis and its clinical significance.]\n\nZhonghua Fu Chan Ke Za Zhi 2006 May;41(5):299-301\n\n4. Midkine is a potent regulator of the catecholamine biosynthesis pathway in mouse aorta.\n\nLife Sci 2006 Mar 21;\n\n5. Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of beta-tectorin gene and in auditory response.\n\nLab Invest 2006 Jul;86(7):645-53\n\n6. Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.\n\nJpn J Clin Oncol 2006 Apr;36(4):207-11